Cytiva and NecstGen form cell and gene therapy collab

Published: 7-Feb-2022
Design & Build Pharmaceutical

NecstGen will provide process development, cGMP manufacturing services up to 200 L, and cleanroom rental


Cytiva, a global life sciences specialist, and NecstGen, aim to accelerate the development of new cell and gene therapies globally via a strategic collaboration.

Cytiva will provide its technologies, services, and solutions to NecstGen, and both organisations will share their knowledge, expertise, and learnings as research programmes are translated into next-generation therapies.

Catarina Flyborg, VP of Cell and Gene Therapy at Cytiva, said: "Cell and gene therapies are transformative medicines and accelerating their development requires harnessing the power of the industry. By sharing our expertise and providing NecstGen with access to our team of specialists, Cytiva will play a critical role in taking translational research from the laboratory to the bedside."

Established in 2020, NecstGen is a non-profit contract development and manufacturing organisation (CDMO) specialising in cell and gene therapies in the Netherlands. It brings the development, production, QC, QA, and QP functions together in a new 4,000 sqm facility in Leiden Bio Science Park, the largest bio-cluster in the Netherlands. The new facility will serve all organisations worldwide, particularly academic and small/large industry enterprises who want to bring their research to the clinical stage.

NecstGen will provide process development, cGMP manufacturing services up to 200 L, and cleanroom rental.

Paul Bilars, CEO, NecstGen, said: "Our partnership with Cytiva will provide us with the flexible and scalable solutions needed by pioneers in the field of cell and gene therapy. Working together, we will accelerate the development of future therapies, bringing these to patients faster."

During the first half of 2021, there were 1,328 regenerative medicine trials underway globally sponsored by non-industry groups such as academic centres and government entities. Small and mid-size enterprises and academic centres play an important role in the development of novel cell and gene therapies. NecstGen addresses the needs of these early-phase therapy developers to help them bring new therapies to patients.

  • Companies:
  • Cytiva
See more

You may also like

Pharmaceutical

Ribobay Pharma to start production of cGMP-level oligonucleotide

Read more
China-based Ribobay Pharma is using Cytiva’s FlexFactory platform for oligo manufacturing to provide cGMP-level oligonucleotide (oligo) CRDMO services to its global clients

Trending Articles

  1. Germfree mobile cleanroom finishes pilot programme for hospital lidocaine production Modular cleanroom expert Germfree and pharma expert ODP are now working to expand a pilot programme after a successful six months of producing medications at North Mississippi Medical Center
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    What is ISO 8 cleanroom classification? Each cleanroom class is denoted by a maximum concentration of particles per cubic meter or cubic foot of air. ISO 8 is the second lowest cleanroom classification
  3. Angstrom Technology Angstrom Technology are the UK & Europe’s leading full-solution provider, for the supply and operation of cleanrooms and critical environments.
  4. The three musketeers of pharmaceutical quality control GMP, GAMP5, and 21CFR11 explained
  5. APIs: Bioreactor hoists with a multipurpose twist Peter Devenny of PalPharma describes the solution for a biotech facility in Switzerland designed to handle filled bioreactors across GMP areas to produce ten metric tons of antibody per year

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Pharmaceutical

Ribobay Pharma to start production of cGMP-level oligonucleotide

China-based Ribobay Pharma is using Cytiva’s FlexFactory platform for oligo manufacturing to provide cGMP-level oligonucleotide (oligo) CRDMO services to its global clients
Pharmaceutical

Cytiva helps Genepeutic Bio install first GMP-certified cell therapy facility in Thailand

The 600 sqm facility has been planned to progress cell therapy in the country
Design & Build

Cytiva supports BioCina with first GMP facility for mRNA in Australia

Cytiva and the University of Adelaide are collaborating with Australia-based pharmaceutical CDMO BioCina to expand its Adelaide facility for mRNA-based vaccines and therapies
Design & Build

Cytiva chooses C2C for cleanrooms in 11,000 sqm facility

C2C has provided design and build services for the Welsh facility, which is investigating some interesting sustainability measures
Design & Build

Cytiva triples single-use consumables capacity in China

The US-based company has launched three new manufacturing lines in under ten months, with an additional eight new lines planned to launch in 2022
Pharmaceutical

Mycenax builds first continuous bioprocessing lab in Taiwan

Cytiva has partnered with biopharma CDMO Mycenax Biotech to expand commercial manufacturing of its first biosimilar
Finance

Cytiva opens life science experience and learning lab in Singapore

The company has decided to open the lab to strengthen the country's local biopharma ecosystem and accelerate Industry 4.0 readiness
Subscribe now